Tamura, Y.; Kumamaru, H.; Tsujino, I.; Suda, R.; Abe, K.; Inami, T.; Horimoto, K.; Adachi, S.; Yasuda, S.; Sera, F.;
et al. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study). Pharmaceuticals 2024, 17, 555.
https://doi.org/10.3390/ph17050555
AMA Style
Tamura Y, Kumamaru H, Tsujino I, Suda R, Abe K, Inami T, Horimoto K, Adachi S, Yasuda S, Sera F,
et al. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study). Pharmaceuticals. 2024; 17(5):555.
https://doi.org/10.3390/ph17050555
Chicago/Turabian Style
Tamura, Yuichi, Hiraku Kumamaru, Ichizo Tsujino, Rika Suda, Kohtaro Abe, Takumi Inami, Koshin Horimoto, Shiro Adachi, Satoshi Yasuda, Fusako Sera,
and et al. 2024. "Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)" Pharmaceuticals 17, no. 5: 555.
https://doi.org/10.3390/ph17050555
APA Style
Tamura, Y., Kumamaru, H., Tsujino, I., Suda, R., Abe, K., Inami, T., Horimoto, K., Adachi, S., Yasuda, S., Sera, F., Taniguchi, Y., Kuwana, M., & Tatsumi, K., on behalf of the Japan Pulmonary Hypertension Registry Network.
(2024). Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study). Pharmaceuticals, 17(5), 555.
https://doi.org/10.3390/ph17050555
